Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sibutramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 16/20 | 0.94 |
| ▸ | SLC6A4 known ✓ | P31645 | 16/20 | 0.94 |
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.94 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.94 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.94 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.94 |
| ▸ | HTR2A | P28223 | 1/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.94 |
| ▸ | HTR2B | P41595 | 1/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.92 |
| ▸ | LMNA | P02545 | 1/20 | 0.92 |
| ▸ | MAPT | P10636 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibutramine SCHEMBL6053421 | 0.99 | SLC6A3 (0.92) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL3707643 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL16312 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL2672138 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL2955 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL2916993 | 0.96 | SLC6A3 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL6431587 | 0.96 | SLC6A3 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL7626175 | 0.96 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL1598 | 0.96 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL7189499 | 0.96 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| EP-1485078-B1 | Milnacipran for the treatment of irritable bowel syndrome | CYPRESS BIOSCIENCE INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7998971-B2 | 2-(2-oxopyrrolidin- 1 -yl)-N-(2,3 -dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide (MKC-231) and a second active ingredient for treating central or peripheral nervous system disorders increase neurogenesis; synergistic; drug addiction, psychological disorders, transplant rejection | BRAINCELLS INC. (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2011091033-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-7985756-B2 | Modulation of neurogenesis by PDE inhibition | BRAINCELLS INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1545489-A4 | TREATMENT OF DEPRESSION SECONDARY TO PAIN (DSP) | CYPRESS BIOSCIENCE INC (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006073292-A1 | INORGANIC ACID SALTS OF SIBUTRAMINE | CJ CORPORATION (KR) | 2006-07-13 | — | — | WO | disclosed |
| EP-1545489-A1 | TREATMENT OF DEPRESSION SECONDARY TO PAIN (DSP) | Cypress Bioscience, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1485078-A1 | NE AND 5-HT REUPTAKE INHIBITORS FOR TREATING VISCERAL PAIN SYNDROMES | Cypress Bioscience, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040034101-A1 | Treatment and prevention of depression secondary to pain (DSP) | CYPRESS BIOSCIENCE, INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004009069-A1 | TREATMENT OF DEPRESSION SECONDARY TO PAIN (DSP) | CYPRESS BIOSCIENCE, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030203055-A1 | Methods of treating visceral pain syndromes | CYPRESS BIOSCIENCE, INC. | 2003-10-30 | — | — | US | disclosed |
| WO-2003077897-A1 | NE AND 5-HT REUPTAKE INHIBITORS FOR TREATING VISCERAL PAIN SYNDROMES | CYPRESS BIOSCIENCE, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203055-A1 | Methods of treating visceral pain syndromes | NPSR1, AANAT, NTSR1 | SLC6A3 40/4885SLC6A4 8/4885SLC6A2 5/4885 |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | SLC6A3 1109/4885SLC6A4 1564/4885SLC6A2 1348/4885 |
| US-20040034101-A1 | Treatment and prevention of depression secondary to pain (DSP) | SLC6A2, SLC6A3, SLC6A4 | SLC6A3 2/4885SLC6A4 3/4885SLC6A2 1/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | SLC6A3 677/4885SLC6A4 792/4885SLC6A2 376/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | SLC6A3 1109/4885SLC6A4 1564/4885SLC6A2 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.